Xenitra Acquires Hong Kong OTC Pharmacy to Expand China Market Reach
Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.
- Acquisition includes Hong Kong pharmaceutical license and ecommerce storefronts
- Enables expansion of OTC medicine offerings in China
- Total acquisition cost reported at ¥469,243
- Leverages established distribution channels and experienced local team
- Builds on recent strategic initiatives in Asian FMCG markets
Strategic Acquisition to Operationalise OTC Business
Xenitra Limited (ASX:XEN) has taken a decisive step to cement its foothold in the Chinese over-the-counter (OTC) medicine market by acquiring 100% of Hong Kong Fukang Trading Co. This move hands Xenitra full control over critical assets, including the Hong Kong Pharmaceutical License PW-2024-00189, a pharmaceutical license premise lease, and a ready-to-go ecommerce shopfront on JD.com.
The acquisition, completed at a total cost of ¥469,243, not only secures regulatory compliance but also integrates Fukang’s existing inventory and logistics arrangements with Hong Kong Kanghong Pharmaceutical Group. This positions Xenitra to swiftly expand its OTC product range and accelerate sales across established channels.
Leveraging Established Channels and Experienced Teams
Since gaining its Hong Kong pharmaceutical wholesale license in December 2025, Xenitra has been laying the groundwork for this expansion. Chairman Anthony Noble emphasised that the acquisition "fully operationalises our OTC business in Hong Kong and in China," highlighting the strategic value of combining regulatory approval with Fukang’s on-the-ground expertise and customer databases.
This integration aligns with Xenitra’s broader strategy to leverage its channel-optimised sales ecosystem that spans B2B wholesale, retail distribution, and major ecommerce platforms across Asia. The company’s recent launch of the OPAL Token and Xen Shop blockchain ecosystem also complements this approach by enhancing product authentication and customer loyalty, as seen in their blockchain-based digital commerce ecosystem initiative.
Positioning for Growth Amid Competitive Market Dynamics
Xenitra’s acquisition of Fukang comes at a time when the Chinese OTC medicine market is both lucrative and highly competitive. By consolidating regulatory licenses and ecommerce storefronts, Xenitra gains a platform to introduce new products seamlessly, leveraging Fukang’s established presence.
While the announcement does not disclose detailed financial projections, the move complements Xenitra’s recent $30 million AUD Danone sales agreement and broader efforts to deepen its B2B reach in China. Together, these steps suggest a concerted push to scale operations and capture market share in the fast-moving consumer goods and nutraceutical segments.
Bottom Line?
Xenitra’s acquisition unlocks immediate operational capacity in China’s OTC sector, but execution risks and market competition will test the company’s ability to convert licenses and assets into sustained growth.
Questions in the middle?
- How quickly can Xenitra scale OTC product offerings leveraging Fukang’s ecommerce and logistics assets?
- What regulatory hurdles remain in expanding OTC medicine sales across China beyond Hong Kong?
- How will Xenitra’s blockchain loyalty initiatives integrate with the newly acquired OTC business?
